Wire · opportunities
Genmab's Rina-S strengthens challenge to Elahere with Phase III ovarian cancer success
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
Genmab's Phase III trial of rinatabart sesutecan (Rina-S) demonstrated significant improvements in progression-free and overall survival for platinum-resistant ovarian cancer patients, outperforming current chemotherapy and broadening the eligible patient population beyond existing FRα-targeted treatments. Genmab plans regulatory discussions and multiple ongoing trials for Rina-S in ovarian and endometrial cancers.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your ovarian cancer drug now faces a stronger competitor widening patient eligibility and improving survival sharply. Prepare for tougher comparisons and accelerated regulatory review as the treatment landscape tightens.
◆ Coverage
1 source · 26 Oct 2026
◆ Related on Wire
◆ Topics